Immunoglobulin G4-related disease (IgG4-RD) is a systemic autoimmune disease, primarily affecting various organ systems such as the pancreas, biliary tree, and liver. The orbit, salivary glands, the thyroid, facial skin, the trigeminal nerve, and the cervical lymph nodes are often affected by IgG4-RD in the head and neck region. 1 Although the ear is rarely affected, few case reports (we found 11 cases, listed in Table 1 ) of otologic manifestation can be found in the literature. [2] [3] [4] [5] [6] We excluded one case in Israel which was presented only in the congress. Of the 11 cases, seven were reported in Asia, and all the 11 cases were treated with steroids, one of them with a combination of methotrexate. Herein, we report the 12 th case of IgG4-RD involving the middle and inner ear. We treated this patient with cyclophosphamide and rituximab, which have never been used to treat otologic symptoms, but were used to treat other organs affected by IgG4-RD. [7] [8] [9] [10] Pure tone audiometry was recorded serially to define the clinical improvement. In addition, we found that early treatment may lead to better outcomes.
CASE REPORT
A 43-year-old male patient complained of right ear fullness that persisted for two years; he did not have type II diabetes mellitus, hypertension, or cholesteatoma. He was diagnosed to have otitis media with effusion; status post tympanocentesis was performed at another hospital at three different times; however, he suffered relapse soon after each treatment procedure. He then visited local medical doctors several times for tympanocentesis. In August 2011, he developed right hearing impairment for which he visited our hospital. An ear-nose-throat specialist confirmed right severe mixed hearing loss by pure tone audiometry ( Figure 1 ). Mastoid computed 
DISCUSSION
In this article, we reported the case of a patient with IgG4-RD who had recurrent otitis media and mixed hearing loss. Cho et al. 2 reported a case of fluctuating mixed-type hearing loss, whereas Gallo et al. 3 reported three cases of sensorineural hearing loss. Later, Cho et al. 11 clarified their findings to report that air-bone gap did not improve with ventilation tube insertion and antibiotics during the initial treatment; rather, it improved with immunosuppressive therapy. This outcome indicated that the disease activity of IgG4-RD paralleled in the middle ear and inner ear depending on the immunosuppressive therapy. We confirmed this observation in our patient, in whom the air-bone gap did not improve after middle ear surgery and antibiotics treatment; however, it improved with immunosuppressive therapy comprising cyclophosphamide and rituximab. To the best of our knowledge, autoimmune inner ear disease manifests as progressive, bilateral, often asynchronous, sensorineural hearing loss that can be associated with vestibular symptoms. 12 Regarding the differential diagnosis, we considered granulomatosis with polyangiitis (Wegener's vasculitis). We assessed the antineutrophil cytoplasmic antibody and pathology results to exclude it. Regarding the patient's left ear, he never complained of fullness sensation or hearing impairment. However, the pure tone audiometry revealed impaired air conduction since July 2014, and the hearing improved after treatment of cyclophosphamide and rituximab in August 2014. Compared with the right ear, we found better improvement in hearing in his left ear (to the normal condition). This observation taught us that earlier immunosuppressive treatment may lead to superior recovery.
Immunoglobulin G4-related disease is rare; however, it can present as recurrent otitis media and mixed hearing loss. We should therefore consider pathological confirmation and further immunosuppressive therapy in a timely manner to prevent hearing impairment in such cases. Moreover, we recommend that an aggressive therapy with glucocorticoids, cyclophosphamide, and rituximab may be useful in treating such patients.
